Baiya Phytopharm Co., Ltd.
Evaluation of Safety, Tolerability, Reactogenicity, Immunogenicity of Baiya SARS-CoV-2 Vax 2 as a Booster for COVID-19
Phase 2
Not yet recruiting
- Conditions
- COVID-19COVID-19 Vaccine
- Interventions
- Biological: 50 μg Baiya SARS-CoV-2 Vax 2Other: Placebo
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Baiya Phytopharm Co., Ltd.
- Target Recruit Count
- 75
- Registration Number
- NCT05873374
- Locations
- 🇹🇭
Queen Saovabha Memorial Institute, Bangkok, Thailand
Evaluation of the Safety, Tolerability, and Reactogenicity of the Baiya SARS-CoV-2 Vax 2 Vaccine for COVID-19 Disease
Phase 1
Active, not recruiting
- Conditions
- COVID-19 Vaccine
- Interventions
- Biological: 50 Baiya SARS-CoV-2 Vax 2Biological: 25 Baiya SARS-CoV-2 Vax 2
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Baiya Phytopharm Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05197712
- Locations
- 🇹🇭
Queen Saovabha Memorial Institute, Bangkok, Thailand
A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19
Phase 1
Completed
- Conditions
- Coronavirus
- Interventions
- Biological: Baiya SARS-CoV-2 Vax 1
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Baiya Phytopharm Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT04953078
- Locations
- 🇹🇭
Chula Clinical Research Center (Chula CRC), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
🇹🇭Queen Saovabha Memorial Institute, Bangkok, Thailand
© Copyright 2025. All Rights Reserved by MedPath